96 related articles for article (PubMed ID: 3020217)
21. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
[TBL] [Abstract][Full Text] [Related]
22. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival.
Skov BG; Fischer BM; Pappot H
Lung Cancer; 2008 Jan; 59(1):88-94. PubMed ID: 17905466
[TBL] [Abstract][Full Text] [Related]
23. Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.
Ellis IO; Hinton CP; MacNay J; Elston CW; Robins A; Owainati AA; Blamey RW; Baldwin RW; Ferry B
Br Med J (Clin Res Ed); 1985 Mar; 290(6472):881-3. PubMed ID: 3919829
[TBL] [Abstract][Full Text] [Related]
24. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
25. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
26. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.
Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC
Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673
[TBL] [Abstract][Full Text] [Related]
27. Steroid receptors in breast cancer.
Desombre ER
Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
Thike AA; Chng MJ; Fook-Chong S; Tan PH
Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
30. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
[TBL] [Abstract][Full Text] [Related]
31. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
32. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
Licznerska BE; Wegman PP; Nordenskjöld B; Wingren S
Breast Cancer Res Treat; 2008 Nov; 112(1):15-23. PubMed ID: 18030614
[TBL] [Abstract][Full Text] [Related]
33. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
34. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.
Elledge RM; Clark GM; Fuqua SA; Yu YY; Allred DC
Cancer Res; 1994 Jul; 54(14):3752-7. PubMed ID: 8033095
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and immunochemical analysis of a breast carcinoma associated antigen defined by the monoclonal antibody NCRC-11.
Price MR
Arch Geschwulstforsch; 1987; 57(3):177-80. PubMed ID: 2441681
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
[TBL] [Abstract][Full Text] [Related]
37. Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status.
Jiang XP; Yang DC; Elliott RL; Head JF
Cytokine; 2000 May; 12(5):458-65. PubMed ID: 10857759
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
Ellis IO; Bell J; Todd JM; Williams M; Dowle C; Robins AR; Elston CW; Blamey RW; Baldwin RW
Br J Cancer; 1987 Sep; 56(3):295-9. PubMed ID: 3663477
[TBL] [Abstract][Full Text] [Related]
39. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients.
Blanco G; Alavaikko M; Ojala A; Collan Y; Heikkinen M; Hietanen T; Aine R; Taskinen PJ
Anticancer Res; 1984; 4(6):383-9. PubMed ID: 6097159
[TBL] [Abstract][Full Text] [Related]
40. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]